-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $270

Benzinga·08/04/2026 11:05:01
語音播報
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $260 to $270.